Check-Cap Ltd (NASDAQ:MBAI) Sees Significant Growth in Short Interest

Check-Cap Ltd (NASDAQ:MBAI) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totaling 127,049 shares, an increase of 93.4% from the May 31st total of 65,685 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average daily volume of 67,215 shares, the short-interest ratio is presently 1.9 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Check-Cap in a research report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Check-Cap has an average rating of “Sell”.

Check-Cap Stock Performance

NASDAQ MBAI remained flat at $1.14 during trading hours on Friday. The company had a trading volume of 51,733 shares, compared to its average volume of 73,522. The business has a fifty day moving average price of $1.52. The company has a market cap of $8.31 million, a PE ratio of -0.41 and a beta of 0.65. Check-Cap has a 1 year low of $0.59 and a 1 year high of $3.92.

About Check-Cap

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.